Clinical Trial Update: Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating allopurinol or febuxostat to prevent contrast-induced acute kidney injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Acute Kidney Injury
• Contrast-induced Nephropathy

Drugs mentioned

• Allopurinol (Allopurinol)
• FEBUXOSTAT (Febuxostat)

Snippet

Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez | Conditions: Contrast-induced Nephropathy, Contrast-induced Acute Kidney Injury | Phase 2 | Status: UNKNOWN